/Companies

ジェイファーマ株式会社

Tokyo, JP · 8 known investors

Find your way into ジェイファーマ株式会社

Sign up to see every warm intro you have to ジェイファーマ株式会社

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ジェイファーマ株式会社 team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.

Founders & leadership

�益𠮷武 益広
𠮷武 益広代表取締役社長 (Representative Director & President)
藤裕藤本 裕
藤本 裕取締役CFO
山寛山本 寛
山本 寛取締役CBO

Investors · 8

Related companies · 2

Companies working in the same space as ジェイファーマ株式会社.

Frequently asked questions

What does ジェイファーマ株式会社 do?
J-Pharma is a drug development company focused on SLC transporter-targeted therapies, with its lead LAT1 inhibitor nanvuranlat (JPH203) in a global Phase 3 trial for biliary tract cancer and other candidates addressing cancer, autoimmune, and rare diseases. The Tokyo-based biotech develops innovative small-molecule drugs and is listed on the Tokyo Stock Exchange Growth Market.
Who founded ジェイファーマ株式会社?
ジェイファーマ株式会社 was founded by 𠮷武 益広.
Who are ジェイファーマ株式会社's investors?
ジェイファーマ株式会社's investors include F-Prime Capital, KSP, Inc., Newton Biocapital, Oita Venture Capital, OSAKA University Venture Capital, SBI Shinsei Corporate Investment, Seibu Shinkin Capital, UntroD Capital.
Where is ジェイファーマ株式会社 headquartered?
ジェイファーマ株式会社 is headquartered in Tokyo, JP.